CEO Today Global Awards

31 www.ceotodaymagazine.com CEO Today Global Awards 2019 SWITZERLAND YVES DECADT CEO and Co-Founder BioLingus CONTACT BioLingus Attn Yves Decadt, CEO Grossmatt 6 CH-6052 Hergiswil Switzerland FIRM PROFILE BioLingus is spearheading the development of non-invasive delivery of biological drugs. Such technology is a breakthrough innovation in for instance treatments of diabetes and inflammatory diseases. Many drugs in these areas have to be injected, and the BioLingus technology allows to deliver these medicines orally without any needles. BioLingus focusses on sublingual administration, because it is a very direct route into the body and may limit variability as compared to classical “oral” administration (via the gut). Examples are the delivery of peptides such a GLP-1 agonist and insulin. Aside from peptide delivery, the Biolingus formulation is also well suited to the delivery of immuno-active molecules, such as low-dose IL-2, which promotes immune-homeostasis (inducing tolerance to allergy or diminishing auto-immunity). From a technical perspective, the BioLingus technology uses advanced bio-engineering technologies to mimic how proteins are stabilized in nature: Some components of the formulation are derived from nature and, in particular, from the seeds of plants in which proteins can be stabilized for a long time in extreme natural conditions; From a processing perspective, the BioLingus technology uses proprietary equipment to generate a process that can be considered as a hybrid between spray-drying and spray-chilling; As such, the BioLingus’ technology is based on three proprietary pillars of a unique formulation, process and equipment. As a company, BioLingus has received several awards. ABOUT YVES DECADT Yves Decadt is CEO and co-founder of BioLingus in Switzerland. Prior and in addition to this role, Yves has held multiple senior level/CEO mandates in small to midsize biotech companies. Before that, Yves worked 18 years at Johnson and Johnson, in different roles and countries. Yves Decadt holds a Masters Degree in Bio-Engineering, a Masters Degree in industrial Business Administration (both from the University of Ghent in Belgium) and a Masters Degree in Pharmacology and Pharmaceutical Medicine (from the Medical Faculty at the Free University of Brussels). He also followed an executive business program at IMD in Lausanne, Switzerland. BioLingus “Inspired by Nature” Grossmatt 6, CH-6052 Hergiswil Switerland info@biolingus.ch www.biolingus.ch